Merck’s snapshot of positive data for frontline lung cancer niche triggers a new scramble for quick Keytruda OK
Merck has caught the big wave on frontline lung cancer, and it plans to ride an early positive signal straight through to a quick OK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
